On BSE, it jumped 4 per cent to Rs 1,020 -- its 52-week high.
The company had posted a net loss of Rs 10.6 crore in the corresponding period of the previous fiscal, Biocon said in a BSE filing yesterday.
Consolidated total income from operations rose to Rs 954.1 crore for the quarter under consideration from Rs 796.2 crore in the same period a year ago.
Commenting on the development, Biocon Chairperson and MD Kiran Mazumdar-Shaw said: "Our performance in Q2 FY17 was led by strong growth across small molecules, biologics and research services.